Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

A recent study from the Women’s Guild Lung Institute at Cedars-Sinai suggests that zinc could help reverse lung damage in patients with idiopathic pulmonary fibrosis (IPF). The findings, published in ...

THIO has gained its generic name and preclinical data on a different form of the cancer drug suggests it could improve ...

Combining BET inhibitors and PARP inhibitors might help patients resistant to chemotherapy, the study suggests.

The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer. Cancer treatment vaccines have been in development since 2010, when the ...

ST316, a β-catenin/BCL9 antagonist, demonstrated safety, target engagement, and early antitumor activity in advanced solid ...

SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a ...

Dizal announces new findings on golidocitinib; to present clinical results at ELCC 2025 in Paris on March 26-29: Shanghai Saturday, March 22, 2025, 17:00 Hrs [IST] Dizal, a biopha ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, ...

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

Greater Manchester has been selected as the site for the trial, as rates of lung cancer ... to helping lung cancer patients receive the right treatment earlier in the patient pathway." ...

In 2024, we made tremendous progress across our pipeline programs, most notably the NDA acceptance of our novel-novel combination of ...